New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown.
New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown.
复制标题
DOI：
10.46697/001c.17692
复制
发表时间：
2020-11-03
期刊：
影响因子：
--
通讯作者：
Picard M
中科院分区：
文献类型：
--
作者：
Dunlap D;Santos RS;McManus DD;Buchholz BO;Hafer NS;Picard M
2020年代以一场罕见的冠状病毒（COVID-19）灾难开始，这场灾难导致了大流行引发的经济衰退和大封锁。作为回应，全世界都在动员资源来检测、治疗和治愈这种病毒。一些政策制定者正在倡导将分布在全球的医疗保健知识遣返回国。在没有治愈COVID-19的方法的情况下，有关冠状病毒相关政策将如何影响国际业务的模糊性仍不清楚。通过多种方法，我们的研究揭示了两个关键的医疗保健行业趋势：临床试验的分散化和去全球化。我们提供可行的战略，不仅可以缓解这些挑战，还可以利用他们的新机遇
The 2020s began with a rare coronavirus (COVID-19) disaster, which led to a pandemic-induced recession and Great Lockdown. In response, there has been a worldwide mobilization of resources to detect, treat, and cure the virus. Some policymakers are advocating for the repatriation of globally distributed healthcare know-how. Without a cure for COVID-19, the ambiguity concerning how coronavirus-related policies will impact international business remains unclear. Through a multi-method approach, our study sheds light on two key healthcare industry trends: decentralization and deglobalization of clinical trials. We offer actionable strategies to not only mitigate these challenges, but also to take advantage of their new opportunities